Zhongshan Hospital, Fudan University
Shanghai, Shagnhai, 200032, China
NCT Number: NCT05857904
This study is a multicenter, prospective, blinded (blinding of clinical evaluators), randomized controlled, event-driven non-inferiority clinical trial. Eligible subjects who meet the inclusion criteria will be registered in the central randomization system and randomized in a 1:1 ratio to either the experimental group (CT-FFR guided group) or the control group (QFR guided group).
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Shanghai, Shagnhai, 200032, China
This study is a multicenter, prospective, blinded, randomized controlled trial with event-driven non-inferiority design (blinding of clinical evaluators). A total of 4,648 participants will be recruited and randomly assigned to the CT-FFR guided group or the QFR guided group in a 1:1 ratio. Patients in the experimental group (CT-FFR guided group) will undergo three-dimensional reconstruction of coronary arteries and CT-FFR calculation using coronary CT angiography (CCTA) images and the RuiXin-FFR software. The CT-FFR results will be interpreted and analyzed by the researchers. If the CT-FFR value is >0.8, patients will receive medical therapy only, while if the CT-FFR value is ≤0.8, patients will undergo further coronary angiography to determine the appropriate treatment strategy (PCI, CABG, or medical therapy), based on the anatomical features of the lesion and CT-FFR results. Patients in the control group (QFR guided group) will undergo invasive coronary angiography (ICA) and QFR calculation based on ICA images. If the QFR value is ≤0.8 and the lesion is suitable for intervention, patients will receive PCI, while if the QFR value is >0.8, medical therapy will be recommended. Both groups will be followed up for clinical outcomes, health economics indicators, and quality of life at 1 month, 6 months, 1 year, 2 years, and 3 years. The occurrence of major adverse cardiovascular events (MACE) will be compared between the two groups. The study will also assess the effectiveness, safety, and economic value of CT-FFR in guiding diagnosis and treatment decisions for patients with stable angina, using QFR guided PCI as a control, with a non-inferiority comparison.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
General exclusion criteria:
Coronary CTA and coronary angiography exclusion criteria:
Regen
CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
Time frame: 1-year
Major Adverse Coronary Event (MACE) rates, defined as:
Time frame: 1-month, 6-month, 2-years, 3-years
Major Adverse Coronary Event (MACE) rates, defined as:
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
All cause death defined as:
Cardiovascular death, non-cardiovascular death, death of unknown cause
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
myocardial infarction (MI) defined as: Spontaneous myocardial infarction , perioperative myocardial infarction
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
Repeat myocardial defined as:Planned revascularization,Unplanned revascularization
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
The American Heart Association/American Stroke Association (AHA/ASA) defines stroke as including the following types:CNS infarction,Ischemic stroke,Silent CNS infarction,Intracerebral hemorrhage,Subarachnoid hemorrhage,Cerebral venous thrombosis
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
The definite and probable stent thrombosis (defined by ARC-2 criteria) including acute, subacute, late, and very late stent thrombosis within a specific time frame.
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
Proportion of non-obstructive CAD detected by ICA examination
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
Cost-effectiveness analysis, cost-utility analysis.
The information collected by the cost indicators is as follows:
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire. Angina status will be assessed using the Seattle Angina Questionnaire.
Time frame: 1-month, 6-month, 1-year, 2-years, 3-years
Cumulative radiation exposure within1-month, 6-month, 1-year, 2-years and 3-years of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA.
Contact information is provided by the study sponsor or research team.
Shanghai Zhongshan Hospital
Other
Clinical Outcomes of CoroNary CTA-Derived FFR Versus ICA-Derived QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain
Acronym: CONFIDENT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04674449
Angina Attacks, Angina Pectoris
Cork, Ireland
View Trial DetailsNCT06325020
Angina Pectoris, Angina, Stable
Edinburgh, United Kingdom
View Trial DetailsNCT05933083
Angina Pectoris, Angina, Stable
San Francisco, California, United States
View Trial DetailsNCT01838148
Angina Pectoris, Angina, Stable
Basel, Switzerland
View Trial Details